The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Descriptive analysis of outcomes in participants with combined hepatocellular-cholangiocarcinoma in the phase 3 KEYNOTE-966 trial.
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Captor Therapeutics Inc; Eisai; Guerbet; Incyte; Ipsen; Jazz Pharmaceuticals; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - AstraZeneca (Inst); Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences; Summit Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Elia Gigante
Honoraria - Gilead, Abbvie, AstraZeneca, Servier, Roche
Consulting or Advisory Role - Sanofi, Sandoz, Abbvie, AstraZeneca
Travel, Accommodations, Expenses - Bayer, Gilead, Roche, AbbVie, Ipsen, Janssen, Galapagos, Pfizer and Orphalan
 
Eric Assenat
Honoraria - AAA HealthCare; AstraZeneca; Bayer; BMS; ipsen; Novartis; Roche; Sanofi; SERVIER
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; BTG; IPSEN; Novartis; Roche; Sanofi; SERVIER
 
Jen-Shi Chen
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; MSD Oncology; Ono Pharmaceutical; Taiho Oncology; Taivex Therapeutics Corporation; TTY Biopharm
(OPTIONAL) Uncompensated Relationships - Taiwan Oncology Society
 
Derk Jan De Groot
Research Funding - Hofmann la Roche, GE Healthcare, Bayer (Inst)
 
Mahmut Gumus
Honoraria - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)
Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst); MSD Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Hyun Woo Lee
No Relationships to Disclose
 
Darryl Outlaw
No Relationships to Disclose
 
Uwe Pelzer
No Relationships to Disclose
 
Chuang Peng
No Relationships to Disclose
 
Thomas Seufferlein
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Falk Foundation; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Arcus Biosciences; BioNTech SE; Boehringer Ingelheim; Cantargia AB; Mirati Therapeutics; NOVOCURE; Olympus Medical Systems; Pierre Fabre; Scandion Oncology; SERVIER; Silexion
Research Funding - Lilly/ImClone (Inst)
Travel, Accommodations, Expenses - Takeda
 
Chris Verslype
Honoraria - Ipsen, AstraZeneca, Novartis
Consulting or Advisory Role - Ipsen, AstraZeneca, Novartis
Travel, Accommodations, Expenses - Ipsen
 
Liis Starkopf
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Usha Malhotra
Employment - Merck
Leadership - Ricovr Healthcare Inc. (I)
Stock and Other Ownership Interests - Merck; Ricovr Healthcare Inc. (I)
 
David Adelberg
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Makoto Ueno
Honoraria - Asca; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Viatris
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Revolution Medicines (Inst); Taiho Pharmaceutical (Inst)